| Autor: |
Vassilev LT; Discovery Oncology, Roche Research Center, Hoffmann-La Roche Inc., Nutley, NJ 07110, USA. lyubomir.vassilev@roche.com, Kazmer S, Marks IM, Pezzoni G, Sala F, Mischke SG, Foley L, Berthel SJ |
| Jazyk: |
angličtina |
| Zdroj: |
Anti-cancer drug design [Anticancer Drug Des] 2001 Feb; Vol. 16 (1), pp. 7-17. |
| Abstrakt: |
A cell-based in vitro screening approach for identification of antitumor drug leads that exploits the differential sensitivity between normal and cancer cells was developed. It is a three-step, high-throughput screen for antiproliferative and/or cytotoxic activity measured by a 7 day MTT [3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromidel assay using small panels of proliferating primary human cells and established cancer cell lines. Proof-of-concept experiments successfully identified 11 known cancer drugs randomly mixed with 5000 test compounds. Application of this screening approach to a library of 110000 compounds allowed for the identification of several novel chemical classes of compounds active against an expanded panel of cancer cell lines in vitro. Two of the compounds representing novel mitotic inhibitors with in vivo potency against established breast cancer xenografts (MDA-MB-435) are reported here. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
